Document Detail


Review of positron emission tomography tracers for imaging of tumor hypoxia.
MedLine Citation:
PMID:  20578843     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hypoxia plays a critical role in tumor development and aggressiveness and is an important prognostic factor for resistance to antineoplastic treatments; therefore, it is required to measure the hypoxic level of tumor for a favorable outcome. The pretherapy information on the oxygenation status of a tumor microenvironment should also have implications for treatment selection. A diffuse distribution of hypoxia in a tumor might suggest a benefit from a systemic approach, such as a hypoxic cell cytotoxin, tirapazamine, or antigrowth factor drugs to combat the limitations of hypoxia. Alternatively, a more focal hypoxia might benefit from a local/regional approach, such as intensity-modulated radiation therapy-based radiation dose escalation to the hypoxic subvolume. This review anticipates that (18)F-FMISO ((18)F-fluoromisonodazole) and (64)Cu-ATSM-positron emission tomography (PET) will prove useful for selecting individual patients for the most appropriate treatment. The advent of new radiotracers has allowed noninvasive assessment of hypoxia, with the most extensively investigated and validated PET radiotracer for hypoxia to date being (18)F-FMISO. This article discusses the relevance and biology of hypoxia in cells and organ systems and reviews the laboratory and clinical applications of (18)F-FMISO and other agents in oncology.
Authors:
Seyed K Imam
Related Documents :
12654433 - Estimating hypoxic status in human tumors: a simulation using eppendorf oxygen probe da...
2766273 - Influence of cellular, microenvironmental, and growth parameters on thermotolerance kin...
9393763 - Molecular evidence that most but not all carcinosarcomas of the uterus are combination ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cancer biotherapy & radiopharmaceuticals     Volume:  25     ISSN:  1557-8852     ISO Abbreviation:  Cancer Biother. Radiopharm.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-28     Completed Date:  2011-01-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9605408     Medline TA:  Cancer Biother Radiopharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  365-74     Citation Subset:  IM    
Affiliation:
Department of Radiology-Nuclear Medicine, Health Sciences Center, Saad Specialist Hospital, Al-Khobar, Saudi Arabia. skimam2003@yahoo.com.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anoxia / diagnosis*,  metabolism
Humans
Neoplasms / diagnosis*,  metabolism
Positron-Emission Tomography*
Radiopharmaceuticals / diagnostic use*,  metabolism
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stability of 3'-deoxy-3'-[18F]fluorothymidine standardized uptake values in head and neck cancer ove...
Next Document:  Digestive challenges for vertebrate animals: microbial diversity, cardiorespiratory coupling, and di...